Low day +100 serum epidermal growth factor levels are associated with acute GvHD after allogeneic hematopoietic cell transplantation.
作者信息
He F, Verneris M R, Cooley S, Blazar B R, MacMillan M L, Newell L F, Panoskaltsis-Mortari A, DeFor T, Weisdorf D J, Holtan S G
机构信息
Blood and Marrow Transplant Program, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Blood and Marrow Transplant Program, Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
出版信息
Bone Marrow Transplant. 2017 Feb;52(2):301-303. doi: 10.1038/bmt.2016.261. Epub 2016 Nov 21.
Abstract
摘要
相似文献
1
Low day +100 serum epidermal growth factor levels are associated with acute GvHD after allogeneic hematopoietic cell transplantation.
Bone Marrow Transplant. 2017 Feb;52(2):301-303. doi: 10.1038/bmt.2016.261. Epub 2016 Nov 21.
2
Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantation.
Biol Blood Marrow Transplant. 2014 May;20(5):730-4. doi: 10.1016/j.bbmt.2014.02.003. Epub 2014 Feb 12.
3
Platelet number and graft function predict intensive care survival in allogeneic stem cell transplantation patients.
Ann Hematol. 2019 Feb;98(2):491-500. doi: 10.1007/s00277-018-3538-8. Epub 2018 Nov 7.
4
Associations between acute GVHD-related biomarkers and endothelial cell activation after allogeneic hematopoietic stem cell transplantation.
Transpl Immunol. 2017 Aug;43-44:27-32. doi: 10.1016/j.trim.2017.06.004. Epub 2017 Jul 5.
5
Lipocalin-2 levels in acute and chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Exp Hematol. 2019 Jun;74:25-32.e1. doi: 10.1016/j.exphem.2019.05.001. Epub 2019 May 10.
6
Single and multiple dose MultiStem (multipotent adult progenitor cell) therapy prophylaxis of acute graft-versus-host disease in myeloablative allogeneic hematopoietic cell transplantation: a phase 1 trial.
Biol Blood Marrow Transplant. 2015 Apr;21(4):720-8. doi: 10.1016/j.bbmt.2014.12.025. Epub 2014 Dec 30.
7
Serum albumin level predicts survival of patients with gastrointestinal acute graft-versus-host disease after allogeneic stem cell transplantation.
Ann Hematol. 2014 May;93(5):855-61. doi: 10.1007/s00277-013-1957-0. Epub 2013 Nov 19.
8
Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome.
Biol Blood Marrow Transplant. 2015 May;21(5):873-80. doi: 10.1016/j.bbmt.2015.01.019. Epub 2015 Jan 23.
9
A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
Biol Blood Marrow Transplant. 2006 Aug;12(8):868-75. doi: 10.1016/j.bbmt.2006.05.006.
10
Soluble human leukocyte antigen G molecule expression in allogeneic hematopoietic stem cell transplantation: good predictor of acute graft-versus-host disease.
Acta Haematol. 2013;130(3):160-8. doi: 10.1159/000350488. Epub 2013 May 22.
引用本文的文献
1
Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802.
Blood Adv. 2018 Aug 14;2(15):1882-1888. doi: 10.1182/bloodadvances.2018017343.
2
Biomarkers in Graft-Versus-Host Disease: from Prediction and Diagnosis to Insights into Complex Graft/Host Interactions.
Curr Hematol Malig Rep. 2018 Feb;13(1):44-52. doi: 10.1007/s11899-018-0433-2.
3
Low EGF in myeloablative allotransplantation: association with severe acute GvHD in BMT CTN 0402.
Bone Marrow Transplant. 2017 Sep;52(9):1300-1303. doi: 10.1038/bmt.2017.89. Epub 2017 Jun 5.
本文引用的文献
1
Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802.
Biol Blood Marrow Transplant. 2015 Jun;21(6):1029-36. doi: 10.1016/j.bbmt.2015.02.018. Epub 2015 Mar 7.
2
Epidermal growth factor receptor expression in acute myelogenous leukaemia is associated with clinical prognosis.
Hematol Oncol. 2012 Jun;30(2):89-97. doi: 10.1002/hon.1002. Epub 2011 Aug 23.
3
Downregulation of serum epidermal growth factor in patients with inflammatory bowel disease. Is there a link with mucosal damage?
Growth Factors. 2010 Dec;28(6):461-6. doi: 10.3109/08977194.2010.527967. Epub 2010 Oct 25.
4
Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers.
J Oncol. 2009;2009:567486. doi: 10.1155/2009/567486. Epub 2009 May 6.
5
Intestinal mucosa remodeling by recombinant human epidermal growth factor(1-48) in neonates with severe necrotizing enterocolitis.
J Pediatr Surg. 2007 Mar;42(3):462-9. doi: 10.1016/j.jpedsurg.2006.10.039.
6
Epidermal growth factor, epidermal growth factor receptors, intestinal growth, and adaptation.
JPEN J Parenter Enteral Nutr. 1999 Sep-Oct;23(5 Suppl):S83-8. doi: 10.1177/014860719902300521.
7
Why is epidermal growth factor present in the gut lumen?
Gut. 1996 Mar;38(3):303-5. doi: 10.1136/gut.38.3.303.
8
Gastric ulcer treatment with intravenous human epidermal growth factor: a double-blind controlled clinical study.
J Gastroenterol Hepatol. 1994;9 Suppl 1:S78-83. doi: 10.1111/j.1440-1746.1994.tb01307.x.
9
Human plasma epidermal growth factor/beta-urogastrone is associated with blood platelets.
J Clin Invest. 1983 Jul;72(1):249-59. doi: 10.1172/jci110964.
10
High dose bolus methylprednisolone for the treatment of acute graft versus host disease.
Blut. 1983 Mar;46(3):125-32. doi: 10.1007/BF00320270.
Zotero 插件